Abstract:Background: Rett syndrome is a neuropediatric disease occurring due to mutations in MECP2 and characterized by a regression in the neuronal development following a normal postnatal growth, which results in the loss of acquired capabilities such as speech or purposeful usage of hands. While altered neurotransmission and brain development are the center of its pathophysiology, alterations in mitochondrial performance have been previously outlined, shaping it as an attractive target for the disease treatment. Methods: We have thoroughly described mitochondrial performance in two Rett models, patients' primary fibroblasts and female Mecp2tm1.1Bird-/+ mice brain, discriminating between different brain areas. The characterization was made according to their bioenergetics function, oxidative stress, network dynamics or ultrastructure. Building on that, we have studied the effect of leriglitazone, a PPARγ agonist, in the modulation of mitochondrial performance. For that, we treated Rett female mice with 75 mg/kg/day leriglitazone from weaning until sacrifice at 7 months, studying both the mitochondrial performance changes and their consequences on the mice phenotype. Finally, we studied its effect on neuroinflammation based on the presence of reactive glia by immunohistochemistry and through a cytokine panel. Results: We have described mitochondrial alterations in Rett fibroblasts regarding both shape and bioenergetic functions, as they displayed less interconnected and shorter mitochondria and reduced ATP production along with increased oxidative stress. The bioenergetic alterations were recalled in Rett mice models, being especially significant in cerebellum, already detectable in pre-symptomatic stages. Treatment with leriglitazone recovered the bioenergetic alterations both in Rett fibroblasts and female mice and exerted an anti-inflammatory effect in the latest, resulting in the amelioration of the mice phenotype both in general condition and exploratory activity. Conclusions: Our studies confirm the mitochondrial dysfunction in Rett syndrome, setting the differences through brain areas and disease stages. Its modulation through leriglitazone is a potential treatment for this disorder, along with other diseases with mitochondrial involvement. This work constitutes the preclinical necessary evidence to lead to a clinical trial.

[Role of Mitochondrial Lesion in Pathogenesis of Sporadic Rett Syndrome].

Mutational Analysis of Mitochondrial DNA of Children with Rett Syndrome

The Study of Mitochondrial Function in A Nonsyndromic Hearing Loss Family Carrying Mitochondria CO1/tRNASer(UCN) 7444G>A and 12S rRNA 1555A>G Mutations

Molecular Mechanisms of Rett Syndrome: Emphasizing the Roles of Monoamine, Immunity, and Mitochondrial Dysfunction

Increased Mitochondrial Mass and Cytosolic Redox Imbalance in Hippocampal Astrocytes of a Mouse Model of Rett Syndrome: Subcellular Changes Revealed by Ratiometric Imaging of JC-1 and roGFP1 Fluorescence

Genes Related to Mitochondrial Functions, Protein Degradation, and Chromatin Folding Are Differentially Expressed in Lymphomonocytes of Rett Syndrome Patients

Mitochondrial DNA Copy Number in Rett Syndrome Caused by Methyl-CpG-Binding Protein-2 Variants

[Application of Long Range Polymerase Chain Reaction and DNA Direct Sequencing in Diagnosis of Rett Syndrome].

Mitochondrial dysfunction and increased reactive oxygen species production in MECP2 mutant astrocytes and their impact on neurons

MECP2 and CDKL5 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome

Clinical Feature of Rett Syndrome and MeCP2 Genotype/phenotype Correlation Analysis

Molecular characteristics of Chinese patients with Rett syndrome.

Transcriptome level analysis in Rett syndrome using human samples from different tissues

Increased ROS Generation and SOD Activity in Heteroplasmic Tissues of Transmitochondrial Mice with A3243G Mitochondrial DNA Mutation.

Genetic Instability and Disease Progression of Indian Rett Syndrome Patients

Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials

miR126-mediated impaired vascular integrity in Rett syndrome

Activity-dependent aberrations in gene expression and alternative splicing in a mouse model of Rett syndrome.

Large Deletion of MECP2 Gene in Two Children with Rett Syndrome

X Chromosome Inactivation in Rett Syndrome and Its Correlations with MECP2 Mutations and Phenotype.